Deoxycholic acid injection

DRUG13 trials

Sponsors

Kythera Biopharmaceuticals, Allergan, Espad Pharmed

Conditions

Flank FatLipomaModerate or Severe Submental FullnessSubcutaneous Fat

Phase 1

Deoxycholic Acid Injection for the Treatment of Superficial Lipomas

CompletedNCT00422188

Kythera BiopharmaceuticalsLipoma

Start: 2007-01-31End: 2007-11-30Updated: 2015-12-10

Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat

CompletedNCT00618722

Kythera BiopharmaceuticalsModerate or Severe Submental Fullness

Start: 2007-08-31End: 2008-10-31Updated: 2015-07-14

Phase 2

Phase 2 Study for the Treatment of Superficial Lipomas

CompletedNCT00608842

Kythera BiopharmaceuticalsLipoma

Start: 2007-11-30End: 2010-01-31Updated: 2016-01-14

Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat

CompletedNCT00618618

Kythera BiopharmaceuticalsModerate or Severe Submental Fullness

Start: 2008-04-30End: 2008-12-31Updated: 2015-07-14

Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study

CompletedNCT01032889

Kythera BiopharmaceuticalsModerate or Severe Submental Fullness

Start: 2009-12-31End: 2010-12-31Updated: 2015-06-15

Phase 3

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

CompletedNCT01294644

Kythera BiopharmaceuticalsModerate or Severe Submental Fullness

Start: 2011-01-31End: 2012-02-29Updated: 2015-06-12

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

CompletedNCT01305577

Kythera BiopharmaceuticalsModerate or Severe Submental Fullness

Start: 2010-12-31End: 2012-01-31Updated: 2015-07-14

Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area

CompletedNCT01426373

Kythera BiopharmaceuticalsModerate or Severe Submental Fullness

Start: 2011-08-31End: 2013-06-30Updated: 2016-01-14

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

CompletedNCT01542034

Kythera BiopharmaceuticalsModerate or Severe Submental Fullness

Start: 2012-02-29End: 2013-08-31Updated: 2015-06-15

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

CompletedNCT01546142

Kythera BiopharmaceuticalsModerate or Severe Submental Fullness

Start: 2012-03-31End: 2013-08-31Updated: 2015-06-15

Patient Experience Study of Deoxycholic Acid Injection

CompletedNCT02007434

Kythera BiopharmaceuticalsModerate or Severe Submental Fullness

Start: 2013-12-31End: 2014-06-30Updated: 2015-07-28

Unknown Phase

Long-term 24-month Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 (Sodium Deoxycholate Injection)

CompletedNCT03682471

AllerganSubcutaneous Fat

Start: 2012-02-14End: 2013-12-13Updated: 2018-09-24

Evaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) for the Treatment of Flank Fat

CompletedNCT07004010

Espad PharmedFlank Fat

Start: 2024-08-01End: 2024-12-30Updated: 2026-01-21

Related Papers

Improvements in Submental Contour up to 3 Years After ATX-101: Efficacy and Safety Follow-Up of the Phase 3 REFINE Trials

Aesthetic Surgery Journal2021-02-2213 citations

Management of Patient Experience With ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat.

2016-11-0120 citations